Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)

Abstract Background The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Methods All patients completing...

Full description

Bibliographic Details
Main Authors: Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein, Yoshiya Tanaka
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Arthritis Research & Therapy
Subjects:
Janus kinase inhibitor
Japanese
Rheumatoid arthritis
Upadacitinib
Online Access:https://doi.org/10.1186/s13075-020-02387-6

Internet

https://doi.org/10.1186/s13075-020-02387-6

Similar Items